Cilostazol: A new drug in the treatment intermittent claudication

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 3, 2007, Pages 181-185

  Kumar, Manoj ^a   Bhattacharya, Vishwanath ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Claudication; Medical management; Peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTITHROMBOCYTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CILOSTAZOL; CINNARIZINE; CLOPIDOGREL; DILTIAZEM; DRUG METABOLITE; ERYTHROMYCIN; INOSITOL NICOTINATE; KETOCONAZOLE; MACROLIDE; MANNITOL; MILRINONE; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; RAPAMYCIN; SERTRALINE; TICLOPIDINE; VASCULOTROPIN; VIRUS VECTOR; WARFARIN;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; KIDNEY DISEASE; LEG BLOOD FLOW; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONVIRAL GENE THERAPY; PATENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; VASODILATATION; VIRAL GENE DELIVERY SYSTEM;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; TETRAZOLES;

EID: 36749058569     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007782418991     Document Type: Review

References (59)

1. Bradbury AW. The Role of Cilostazol (Pletal ™) in the Management of Intermittent Claudication. Int J Clin Prac 2003; 57 (5): 405-409.
2. Whitehouse, M.J.: US20077186407 (2007).
3. Criqui MH. Systemic Artherosclerosis risk and the mandate for intervention in artherosclerotic peripheral arterial disease. Am J Cardiol 2001; 88: 43J-47J
4. Sternlicht, A.: WO07044435 (2007).
5. Leng GC, Lee AJ, Fowkes FGR, et al. Review of the symptoms, diagnosis and best medical treatment of intermittent claudication in the community. Int J Epidemiol 1996; 25: 1172-1181, Medicine Matters In General Practice 2006; 113.
6. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-128.
7. Dormandy JA, Heeck L, Vig S. The fate of patients with critical leg ischaemia. Semin Vasc Surgery 1999; 12: 142-147.
8. Newman AB, Sutton-Tyrell K, Rutan GH, Locher J, Kuller LH. Lower extremity arterial disease in elderly subjects with systolic hypertension. J Clin Epidmiol 1999; 44: 15-20.
9. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Ger Intern Med 1997; 12: 209-215.
10. Clark AL, Bryne JC, Nasser A, McGroarty E, Kennedy JA. Cholesterol in peripheral vascular disease-a suitable case for treatment? QJM 1999; 92: 219-222.
11. Olin JW. Management of patients with intermittent claudication. Int J Clin Pract 2002; 56(9): 687-693.
12. Fernadez Jr BB. A rational approach to diagnosis and treatment of intermittent claudication. AM J Med Sci 2002; 323(5): 244-251.
13. Donnelly R. Assessment and management of intermittent claudication: Importance of secondary prevention. Int J Clin Pract 2001; 1192-99.
14. Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3(2): 117-138.
15. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20: 900-906
16. cited in Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3(2): 117-138.
17. Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by inducton of p56 and p21. Hypertension 2000; 35(20): 237-243
18. cited in Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3(2): 117-138.
19. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Bio 1998; 18(12): 1942-1947.
20. Lee TM, Su SF, Hwang JJ, et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role foe interleukin-6. Atherosclerosis 2001; 158(2): 471-476.
21. Flaumenhaft, R.C.: US20077166612 (2007).
22. Mcmichael, J., Sauniere, J.-F.: US20077196058 (2007).
23. Ikeda Y, Kikuchi M, Murakami H, et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet function ex vivo randomised, double-blind cross-over study. Arneimittelforschung 1987; 37 (5): 563-566,
24. cited in Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3(2): 117-138.
25. Tamai Y, Takami H, Nakahata R, et al. Comparison of the effects of acetylsalicylic acid, ticlopine and cilostazol on primary haemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999; 29(5): 269-276.
26. Tani T, Sakuari K, Kimura Y, et al. Pharmalogical manipulation of tissue cyclic AMP by inhibitors; effects of phospodiesterase inhibitors on the functions of platlets and vascular endothelial cells. Adv Second Messanger Phosphoproten Res 1992; 25: 215-227.
27. Yasuda K, Sakuma M, Tanable T. Haemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 1985; 35(7a): 1198-1200,
28. cited in Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3(2): 117-138
29. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioschler Throm Vasc Biol 1998; 181: 942-947.
30. Lee TM, Su SF, Tsai CH, et al. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factors in patients with intermittent claudication. Clin Sci 2001; 101: 305-311.
31. Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001; 44: 1034-1042.
32. Falotico, R., Zhao, J.Z.: EP1782851 (2007).
33. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthly males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinetics 1999; 37(2): 1-11.
34. Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on sigle dose cilostazol pharmacokinetics. Clin Pharmacokinetics 1999; 37(2): 13-23.
35. Abbas R, Chow CP, Browder NJ, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 2000; 19(3): 178-184.
36. Bramer SL, Tata PNV, Mallikaajun S, et al. Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Pharm Res 1997; 14(11): S612.
37. Suri A, Forbes WP, Bramer SL. Pharmacokinetics of multiple-dose oral cilostazol in middle-aged men and women. J Clin Pharmacol 1998; 38(2): 144-150.
38. Mallikuujun S, Forbes WP, Bramer SL. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. Clin Pharmacokinetics 1999; 37(2): 33-40.
39. Ostuka Pharmaceuticals. Summary of product characteristics. Pletal 2001.
40. Bramer SL, Forbes WP. Effects of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. Clin Pharmacokinetics 1999; 37(2): 25-32.
41. Parker M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475.
42. Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmocol 1999; 23(3): 48-52.
43. Gibiansky E, Mallikaarjun S, Bramer SL. Nonparametric population pharmacokinetics of cilostazol. Pharm Res 1997; 14(11): 515-516.
44. Ostuka Pharmaceuticals. Pletal. Prescribing Information. URL: www.pletal.com.pro/0_7.asp
45. Suri A, Bramer SL. Effect of orneprazole on the metabolism of cilostazol. Clin Pharmacokinetics 1999; 37(2): 53-59.
46. Kim J-S, Lee KS, Kim YI, et al. A randomised crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11: 600-602.
47. Yoshida, S., Sudo, T.: WO07052841 (2007).
48. Cleanthis M, Bhattacharya V, Smout J, et al. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise induced platelet activation. Yearbook of Society of Academic and Research Surgery 2005.
49. Soula, G., Guimberteau, F.: WO07036809 (2007).
50. Mallikaarjun S, Forbes WP, Bramer SL. Interaction potential and tolerability of the co administration of cilostazol and aspirin. Clin Pharmacokinetics 1999; 37(2): 87-93.
51. Mallikaarjun S, Forbes WP, Bramer SL. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet 1999; 37(Suppl. 2): 87-93
52. Toda, M., Mukai, T.: WO07001086 (2007).
53. Regensteiner JG, Ware JE, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomised controlled trials. JAGS 2002; 50: 1939-1946.
54. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. 2000; 109: 523-530.
55. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomised, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2000; 90: 1314-1319.
56. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87: 28D-33D.
57. Norgren L, Hiatt WR, et al. TASC II Inter-society Consensus on Peripheral Arterial Disease. 2007; S28-31.
58. Lederman R, Mendelsohn F, Annderson R, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359(9323): 2053-2058.
59. Rajagopalan S, Mohler EI, Lederman R, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomised, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108(16): 1933-1938.